Navigation Links
N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
Date:3/13/2013

BOULDER, Colo., March 13, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF).  The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation, the most common and serious form of CF.

The clinical study announced today is being conducted in collaboration with the Cystic Fibrosis Foundation's Therapeutics Development Network (TDN), and the lead principal investigator for the study is Scott Donaldson , M.D., at The University of North Carolina, Chapel Hill.  The first patient was dosed this week at National Jewish Health in Denver.  The primary objective of the study is to evaluate the safety of repeat doses of N6022.  Secondary and exploratory objectives include the evaluation of N6022 serum levels, lung function, and other markers of disease activity in CF.

"We are indebted to the cystic fibrosis clinicians and nurses who have given us such valuable advice, to the members of the TDN who have been instrumental in getting this first trial started, and to the patients who will be volunteering for participation. With this first trial, we look forward to paving the way to a new class of therapy for cystic fibrosis," said Charles Scoggin , M.D., President and Chief Executive Officer of N30 Pharma.

About Cystic FibrosisCystic fibrosis is the most common, life-threatening, genetic disease of Caucasians, affecting approximately 30,000 people in the United States and 70,000 people worldwide.  Approximately 48% of the total CF patient population, in the U
'/>"/>

SOURCE N30 Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... in China , today announced that ... issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai ... that on May 21, 2013, Ms. Siu ... shareholders of the Company, and her spouse, Mr. Tung ...
(Date:5/24/2013)... , May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... will participate in the Deutsche Bank Health Care Conference ... Waterfront Hotel.  Mr. Adrian Adams , ... an overview of the Company and its product pipeline ...   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
(Date:5/24/2013)... YORK , May 24, 2013 In accordance ... Rules and Rule 14e-1 of the United States Exchange Act, ... its original offer for Elan Corporation (NYSE: ELN). ... Limited ("Royalty Pharma") made an offer for the entire of ... Corporation, plc ("Elan") (the "Original Offer").  On ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... InfoLogix, Inc. (Pink Sheets: IFLG ), ... the healthcare and commercial industries, announced today that it ... Faire and Regional Conference, sponsored by HIMSS South Florida ... Grand Hotel in Davies, FL (situated North of Miami) ...
... Mass., Oct. 25 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), ... and development, focusing on the early diagnosis and preventive ... it has been selected by Windhover as one of ... the cardiovascular/metabolic category. This announcement is part of the ...
Cached Medicine Technology:InfoLogix to Present at South Florida Healthcare Trade Faire & Regional Conference 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3
(Date:5/23/2013)... PHILADELPHIA, May 24, 2013 -- High blood glucose is ... of intensive insulin therapy (IIT) to control hyperglycemia is ... does not show a consistent benefit and even shows ... the American College of Physicians, (ACP) Clinical Guidelines Committee ... the American Journal of Medical Quality . , ...
(Date:5/23/2013)... Littleton, CO (PRWEB) May 23, 2013 ... environment, Special Operations Forces and law enforcement need an ... Night Vision Security Enhancer, Night VISER , is ... illuminator and motion sensing system to increase border and ... for Night VISER have more than tripled over the ...
(Date:5/23/2013)... May 24, 2013 In his pulse-quickening novel, ... the question, “Do you trust your government?” , In the ... killed en route to London ’s Heathrow Airport. His ... is left waiting for him to arrive at his ... death surfaces, Alan has doubts about the government’s report. When ...
(Date:5/23/2013)... Orange County film studio and visual effects ... light leaks for Apple's Final Cut Pro X today. ... no longer have to worry about matching up the movement ... Said Christina Austin, CEO of Pixel Film Studios, "You have ... look." , ProLeak from Pixel Film Studios allows users to ...
(Date:5/23/2013)... Branford, CT (PRWEB) May 23, 2013 ... patient satisfaction and perception management tools, and ASCA, ... to develop the new ASCA Benchmarking Program. ... in surveying technology and national benchmarking experience to ... with a comprehensive, state-of-the-art benchmarking tool. , “Voyance ...
Breaking Medicine News(10 mins):Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3
... Researchers at Cambridge University in the UK have discovered ... play a significant role in triggering breast cancer in ... new methods of targeting younger women at higher-than-average risk ... with mammography before they reach 50 - the age ...
... of 'monkey see, monkey do.' Researchers at Ohio University ... red, they began to develop red and orange skin and ... such as macaques and leaf monkeys, all have trichromatic vision, ... red colors. Primatologists have disagreed about whether this type of ...
... a say in how they quit are more likely to ... new research at the University of Rochester . ... the University of Rochester School of Medicine and Dentistry, will ... demonstrate patient involvement in a quit plan leads to smokers ...
... an enzyme called Cdk5 in their brains by using the ... adept at learning and quicker at figuring out the changes ... ,"Its pretty rare that you make mice smarter, so ... senior study author Dr. James Bibb, Assistant Professor of Psychiatry, ...
... Published today in the American Diabetes Association journal Diabetes ... that the care of elderly patients with type 1insulin ... facilities fails to meet ADA Standards of Care. ... Intensity of Care?, a study authored Jay Shubrook, D.O., ...
... are the bad guys that help bacterial pathogens do their ... system. In essence, they knock down the front door of ... ,Now, researchers at the University of California, San Diego (UCSD) ... an effector protein called YpkA, one of several effectors of ...
Cached Medicine News:Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3Health News:Color Vision Drove Primates to Develop Red Skin and Hair, Study Finds 2Health News:Choice is a Key Element in Success for Smokers Who Want to Quit 2Health News:Scientist Found New Mechanism for Brain Learning 2Health News:Diabetics in Nursing Homes Need Improved Care 2Health News:Diabetics in Nursing Homes Need Improved Care 3Health News:How Plague-Causing Bacteria Disarm Host Defense 2
... designed specifically for posteror ... injection of silicone oil ... Special high pressure tubing ... cannula. May also be ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Stainless steel probes, 23G x4 1/2in (.60mm x 11cm) Silicone tubing, length 14in (35cm), ID: .012in (.30mm) OD: .025in (.60mm...
...
Medicine Products: